We are boosting cell rejuvenation to treat currently incurable neurodegenerative and rare genetic diseases
Autophagy (from the Ancient Greek: ”self-eating”) is the cell’s main method for recycling damaged components and this process declines with age. There is compelling evidence that boosting autophagy leads to increased healthspan and lifespan, while impaired autophagy drives many serious diseases.
We are enhancing healthspan, by building an unbiased data-driven drug discovery engine
We’re letting our proprietary data guide us in new and unexpected directions to find better ways to restore autophagy. This approach allows us to uncover novel biology and gives us fundamental insights into how the cell controls this process. It’s led us very quickly to first in class, disease modifying programs which have exciting therapeutic activity.
Introducing Samsara
Rejuvenating cells
Restoring health
Reversing disease
The Lysoseeker™ Platform
A unique approach for discovering new autophagy therapeutics.
Neurodegeneration
What if we could tackle the cause of Alzheimer’s and Parkinson’s Disease?
Rare Monogenic Disease
What if we could offer real hope for serious rare genetic diseases?
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology.
Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
Meet the Neuro Team – Modelling Neurodegeneration in a Dish
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy